Opinion

Video

Current Front-Line Treatment Options for CLL in 2023

Author(s):

Catherine C. Coombs, MD,Brian T. Hill, MD, PhD

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
View More
Related Content
Chronic Lymphocytic Leukemia | Image credit: © LASZLO – stock.adobe.com
April 24th 2025

Meta Analysis Shows Efficacy Trend Favoring Zanubrutinib in High-Risk R/R CLL

Alexey Danilov, MD, PhD, Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director, Early Phase Therapeutics Program, the Systems Clinical Trials Office, co-director, Toni Stephenson Lymphoma Center, professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope; Susan M. O'Brien, MD, associate director, Clinical Science, Chao Family Comprehensive Cancer Center, medical director, Sue & Ralph Stern Center for Clinical Trials & Research, professor, medicine, Division of Hematology/Oncology, University of California Irvine School of Medicine
December 31st 2024

Explore the Evolving Role of BTK Inhibitors in CLL: With Alexey Danilov, MD, PhD; and Susan M. O'Brien, MD

Nogapendekin alfa inbakicept sBLA in NMIBC has been filed to FDA for review, a bexmarilimab combination elicits responses in MDS, and more from OncLive.
April 19th 2025

The OncFive: Top Oncology Articles for the Week of 4/13

Onyee Chan, MD, hematologist/oncologist, Moffitt Cancer Center Magnolia Campus; Bradley D. Hunter, MD, medical director, Oncology, director, Immune Effector Cell Therapy, Intermountain Healthcare
December 24th 2024

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.
April 13th 2025

Five Under 5: Top Oncology Videos for the Week of 4/6

Chronic Lymphocytic Leukemia | Image Credit: © ivlianna – stock.adobe.com
April 4th 2025

Acalabrutinib Produces High ORR in Chinese Patients With R/R CLL